8-K: BioSig Technologies Pivots to Real-World Asset Tokenization with Streamex Acquisition, Announces New Leadership and Strategic Advisors

BioSig Technologies, Inc. has signed a definitive share exchange agreement to acquire Streamex Exchange Corporation, marking a strategic pivot into real-world asset tokenization and commodity markets, accompanied by significant leadership changes and a planned capital raise.

Summary

• BioSig Technologies, Inc. (Nasdaq: BSGM) has entered into a definitive share purchase agreement to acquire Streamex Exchange Corporation, a privately held company specializing in real-world asset (RWA) tokenization, particularly in commodity markets.
• Upon closing, Streamex will become a wholly-owned subsidiary of BioSig.
• Streamex shareholders will initially receive 109,070,079 exchangeable shares of BST Sub ULC (a BioSig subsidiary) at a ratio of 2.05 exchangeable shares for each Streamex share.
• These exchangeable shares are convertible into BioSig common stock on a one-for-one basis, subject to adjustments.
• Initially, Streamex shareholders will receive exchangeable shares convertible into no more than 19.9% of BioSig's outstanding common stock (pre-transaction basis), in compliance with Nasdaq listing rules.
• Following shareholder approval of certain Parent Stockholder Matters, Streamex shareholders will become entitled to receive an aggregate total number of shares equal to 75% of BioSig's fully diluted common stock outstanding as of the Share Purchase Agreement date.
• If shareholder approval is not obtained prior to the six-month anniversary of the closing, the exchange ratio will adjust from 1.0 to 1.25.
• The transaction is intended to qualify as a reorganization under Section 368(a) of the Internal Revenue Code.
• BioSig will authorize a new series of preferred stock, 'Special Voting Preferred Stock,' to be held by a Trustee, which will carry voting rights for the benefit of Exchangeable Shareholders, equivalent to their economic interest, until the full common stock exchange is approved.
• The company plans to adopt a new stock incentive plan, reserving 10% of the fully-diluted outstanding equity interests of the combined entity for employees, directors, and consultants, following shareholder approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is undertaking a significant strategic pivot into a high-growth market (RWA tokenization) with new, experienced leadership and strong strategic advisors. This transformation is presented as a 'transformational chapter' aimed at 'building long-term shareholder value.' However, the inherent risks of such a major shift, including substantial dilution for existing shareholders and the need for future shareholder approval, temper the overall positive outlook.

Positives

• The acquisition represents a significant strategic pivot for BioSig into the high-growth real-world asset (RWA) tokenization market, specifically targeting the US$142.85 trillion global commodity market.
• New leadership from Streamex, including Henry McPhie as incoming CEO and Morgan Lekstrom as Chairman of the Board, brings specialized expertise in financial, commodities, and blockchain industries.
• The transaction aims to unlock new value by bringing commodities on-chain through secure and scalable tokenization solutions, enhancing liquidity, accessibility, and efficiency.
• The company plans to raise at least $5 million in capital post-closing, which could provide necessary funding for the new strategic direction.
• The addition of prominent strategic advisors like Frank Giustra (commodities), Mathew August (US Capital Markets), and Mitchell Williams (US Capital Markets) lends credibility and experience to the new venture.

Negatives

• Existing BioSig shareholders will experience significant dilution, with their collective ownership decreasing to 25% of the fully diluted common stock after shareholder approval of the transaction.
• The full economic benefit for Streamex shareholders (75% ownership) is contingent on BioSig shareholder approval, introducing a potential risk if not obtained.
• The transition from a medical technology company to an RWA tokenization company represents a complete business transformation, which carries inherent risks related to market acceptance, execution, and regulatory compliance in a new industry.
• The document does not provide specific financial projections or current financial performance metrics for Streamex, making it difficult to assess the immediate financial impact of the acquisition.

Risks

• The transaction's full realization, particularly the 75% ownership for Streamex shareholders, is contingent on obtaining BioSig stockholder approval of the Parent Stockholder Matters.
• Failure to obtain stockholder approval within six months of closing will result in an adjustment of the exchange ratio from 1.0 to 1.25, potentially impacting the value proposition for Streamex shareholders.
• The company must maintain compliance with Nasdaq's listing criteria, including potentially filing an initial listing application for its common stock due to change of control rules.
• The success of the new RWA tokenization business is subject to market acceptance, regulatory developments in the blockchain and commodity tokenization space, and the company's ability to execute its new strategy.
• The forward-looking statements are subject to various known and unknown risks and uncertainties, including the ability to realize the benefits of the transaction and maintain Nasdaq compliance.

Future Outlook

The combined company, to be led by Streamex's co-founders, aims to revolutionize commodity finance by bringing commodity markets on-chain through secure and scalable real-world asset tokenization solutions. The company intends to raise at least $5 million in capital post-closing to support this new strategic direction. The full realization of the new ownership structure and certain corporate governance changes are contingent on future BioSig stockholder approval.

Management Comments

• Anthony Amato, current CEO of BioSig, stated: 'After a year marked by intense focus, disciplined execution, and steadfast commitment, I’m pleased to announce that we have signed a definitive agreement to combine with Streamex. This marks a pivotal milestone in our ongoing strategy to restore and build long-term shareholder value. This journey hasn’t been without its challenges—but it has also been defined by toughness, learning, and progress. But today, we enter what promises to be the most transformational chapter in our company’s history. I want to thank our incredible employees, our leadership team, and our board of directors for their unwavering dedication and resilience throughout this journey. And to our shareholders: this is the moment we’ve been working toward. We believe this business combination significantly strengthens the foundation of your investment and positions us for sustained momentum and future growth.'
• Henry McPhie, incoming CEO of the combined company, added: 'Since announcing the LOI for the transaction, we’ve received an overwhelmingly positive response from the market, reflecting strong investor confidence in the value and potential of this transaction. With the signing of the definitive agreement, we’re thrilled to move ahead with the BioSig team to complete the combination and bring Streamex to the public market.'

Industry Context

This transaction positions BioSig Technologies, previously a medical technology company, to enter the burgeoning real-world asset (RWA) tokenization market, specifically focusing on commodities. This move aligns with a broader trend in the financial industry to leverage blockchain technology for increased liquidity, transparency, and efficiency in traditional asset classes. The global commodities market, valued at approximately US$142.85 trillion, presents a substantial opportunity for tokenization solutions that bridge traditional finance with the digital economy.

Comparison to Industry Standards

• The document does not provide specific comparable companies or projects within the RWA tokenization space to benchmark Streamex's current performance or market position against industry standards.
• The stated goal of 'revolutionizing commodity finance' and 'unlocking new opportunities for investors and institutions worldwide' suggests an ambition to be a leader in this emerging sector, but concrete comparative results are not presented.
• The valuation implied by the 75% post-approval ownership for Streamex shareholders, relative to BioSig's existing market capitalization, would be a key metric for industry comparison, but specific market caps are not provided in the filing.

Management Changes

Corporate Governance

Related Party Transactions

• Anthony Amato, current CEO and a director of BioSig, will receive a severance payment of $400,000 and full acceleration of all outstanding equity awards upon his resignation as CEO in connection with the transaction.
• Anthony Amato will enter into a 'Right to Place' letter agreement, agreeing not to sell his BioSig securities for 12 months without first offering them to the company, which has a limited right to purchase them.

Stakeholder Impact

• **Shareholders (Existing BioSig):** Will experience significant dilution, with their collective ownership decreasing to 25% of the fully diluted common stock post-approval. However, they gain exposure to the RWA tokenization market, which could offer substantial growth potential.
• **Shareholders (Streamex):** Will become the majority owners (75% fully diluted post-approval) of the combined public company, gaining liquidity and access to public markets for their RWA tokenization business.
• **Employees (BioSig):** Will see a change in executive leadership and a strategic shift in the company's core business. A new incentive plan is proposed, which could benefit employees of the combined entity.
• **Employees (Streamex):** Will become part of a publicly traded company, potentially gaining access to public market compensation structures and increased visibility.
• **Management:** Significant changes in executive roles and board composition, with Streamex's leadership taking the helm, indicating a clear shift in strategic direction and control.
• **Customers/Market:** The company will pivot from medical technology to RWA tokenization, targeting commodity markets, which will impact its customer base and market focus.

Next Steps

• BioSig Technologies, Inc. will seek stockholder approval for the 'Parent Stockholder Matters,' including the full share exchange for Streamex shareholders, issuance of Special Voting Preferred Stock, a new incentive plan, and amendments to the certificate of incorporation and bylaws.
• If stockholder approval is not obtained within six months of closing, the exchange ratio for Streamex shareholders will adjust from 1.0 to 1.25.
• BioSig will file an initial listing application for its common stock with Nasdaq, if required by change of control rules.
• After the closing, BioSig intends to conduct a fundraising initiative to raise at least $5 million.
• A new stock incentive plan will be adopted or amended following stockholder approval, reserving 10% of the fully-diluted outstanding equity interests.
• The company's name will be changed to Streamex Exchange Corporation after stockholder approval of the Parent Stockholder Matters.

Key Dates

Keywords

Real-World Asset Tokenization, RWA, Commodity Markets, Blockchain, Share Exchange Agreement, Acquisition, Strategic Pivot, Corporate Governance, SEC Filing, Nasdaq Listing, Capital Raise, Executive Change, Stock Dilution, Special Voting Preferred Stock